The role of low-molecular-weight heparins in treating thrombosis

Journal of Supportive Oncology

Volumn 4, Issue 3, 2006, Pages 123-124

  Lee, Agnes Y Y ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVITAMIN K; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR; WARFARIN;

BLEEDING; CANCER; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; LONG TERM CARE; LUNG EMBOLISM; NOTE; PATHOGENESIS; PRIMARY PREVENTION; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RISK FACTOR; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; NEOPLASMS; VENOUS THROMBOSIS;

EID: 33645763461     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
2. Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005;128:291-302.
3. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349;146-153.